Key result
Novel cell-based assay quantifies surface ACE2 activity, identifying marked substrate impairment in R273Q variants.
Why the study?
Disease-associated genetic variants of ACE2 are increasingly identified but remain poorly characterized, necessitating improved methods for functional assessment.
A novel fluorometric cell-based assay enables high-throughput evaluation of surface-expressed ACE2 catalytic activity, facilitating the study of ACE2 variants in cardiovascular and other diseases.
Angiotensin-converting enzyme II (ACE2) is a monocarboxypeptidase expressed throughout multiple tissues and its catalysis of bioactive peptides regulates the renin-angiotensin system mediating blood pressure homeostasis. ACE2 is implicated in a variety of diseases, including obesity, diabetes, and cardiovascular diseases, and is the obligate entry receptor for SARS-CoV-2 infection. Disease-associated genetic variants of ACE2 are increasingly being identified but are poorly characterized. To aid this problem, we introduce a fluorometric cell-based assay for evaluating surface-expressed ACE2 catalytic activity that preserves the native glycosylation of the host environment and is amenable to high-throughput analysis of ACE2 variants in multi-well plates. We demonstrate sensitivity to detecting catalysis of the key ACE2 substrates, Angiotensin II, Apelin-13, and des-Arg9-bradykinin, and impact of a catalytically-deficient ACE2 variant. Normalizing catalytic measures to surface ACE2 expression accounts for variability in ACE2 variant transfection, surface delivery or stability. This assay provides a convenient and powerful approach for investigating the catalytic characteristics of ACE2 variants involved in cardiovascular peptide cascades and homeostasis of multiple organs.
No takes yet. Share an insight, caveat, or question.
Meyers et al. (2023) studied this question. Cell-based assay for ACE2 catalytic function vs. Untransfected cells or catalytically-deficient variant R273Q was evaluated on ACE2 catalytic activity (phenylalanine production). A novel cell-based assay successfully quantified the catalytic activity of surface-expressed ACE2, demonstrating significantly reduced metabolism of key substrates by the R273Q variant (P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from Scientific Reports